

# THE U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION AND TREATMENTS



**BIO145A**  
**August 2015**

Peggy Lehr  
***Project Analyst***

ISBN: 1-62296-125-0



**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481 USA**  
**866-285-7215 (toll-free within the USA),**  
**or (+1) 781-489-7301**  
**[www.bccresearch.com](http://www.bccresearch.com)**  
**[information@bccresearch.com](mailto:information@bccresearch.com)**

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
REASONS FOR DOING THE STUDY	2
STUDY GOALS AND OBJECTIVES	2
INTENDED AUDIENCE	3
SCOPE AND FORMAT	3
METHODOLOGIES AND INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
DETECTION	6
HANDHELD DEVICES	7
TREATMENT	7
CONTRIBUTING FACTORS TO BIODEFENSE-RELATED PATHOGEN IDENTIFICATION MARKET	7
U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION PRODUCTS	7
<i>SUMMARY TABLE U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION MARKET, BY TYPE OF DETECTION, 2016 AND 2021 (%)</i>	8
CHAPTER 3 INDUSTRY OVERVIEW	10
HISTORY AND CURRENT STATE OF RAPID PATHOGEN IDENTIFICATION AND TREATMENTS	10
DELIVERY AND DETECTION	11
AIRBORNE	11
EXPLOSIVES	11
FOOD AND WATER CONTAMINATION	11
ABSORPTION OR INJECTION	11
POTENTIAL BIOLOGICAL PATHOGENS	12
CLASS A	12
<i>TABLE 1 U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS A</i>	12
<i>TABLE 2 CLASS A PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD</i>	13
CLASS B	13
<i>TABLE 3 U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS B</i>	13
<i>TABLE 4 CLASS B PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD</i>	14
CLASS C	14
<i>TABLE 5 U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS C</i>	14
<i>TABLE 6 CLASS C PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD</i>	15
RAPID IDENTIFICATION PRODUCTS	15
<i>TABLE 7 LIMITATIONS OF SOME COMMON ANALYSIS METHODS</i>	16

<b>TOPIC</b>	<b>PAGE NO.</b>
PCR	16
QPCR	16
MICROARRAY	17
MASS SPECTROMETRY	17
IMMUNOMAGNETIC SEPARATION (IMS)	17
SENSING TECHNOLOGY	18
<i>TABLE 8 CHARACTERISTICS OF BIOSENSORS</i>	18
FLUCTUATION-ENHANCING SENSING (FES)	19
SENSING OF PHAGE-TRIGGERED ION CASCADES (SEPTIC)	19
NANOPORE	19
IMMUNOASSAY	20
Enzyme-linked Immunosorbent Assay (ELISA)	20
Lateral Flow Tests	20
DETECT-TO-WARN SYSTEMS	21
<i>TABLE 9 DETECT-TO-WARN MONITORING SYSTEMS</i>	21
TREATMENTS	22
VACCINES	22
<i>TABLE 10 VACCINES FOR PATHOGENS, BY DISEASE OR CONDITION, BRAND NAME AND MANUFACTURER, 2014</i>	22
PHARMACEUTICALS TO TREAT BIODEFENSE-RELATED PATHOGENS	23
<i>TABLE 11 COMMON PHARMACEUTICALS TO TREAT BIODEFENSE-RELATED PATHOGENS BY NAME, MANUFACTURER, DISEASE OR CONDITION, 2015</i>	23
PLANNING AND RESPONSE TO BIOTERRORISM EVENT	23
BIOSURVEILLANCE	24
MICROBIAL FORENSICS	24
ROLE OF GOVERNMENT, UNIVERSITIES AND PRIVATE FUNDING IN PRODUCT DEVELOPMENT	25
<i>TABLE 12 MAJOR GOVERNMENT FUNDERS OF R &amp; D WITH AMOUNT FUNDED, 2012-2014 (\$ BILLIONS)</i>	25
<i>FIGURE 1 U.S. GENERAL R&amp;D FUNDING SOURCES, 2014 (%)</i>	26
FUNDING OPTIONS	26
U.S. GOVERNMENT FUNDING	26
Department of Homeland Security Project Biowatch	26
Department of Defense	27
UNIVERSITY/INDUSTRY FUNDING	27
INDUSTRY CHANGES	27
<i>TABLE 13 SELECTED MERGERS AND ACQUISITIONS IN THE BIODEFENSE IDENTIFICATION INDUSTRY, JANUARY 2013-JUNE 2015</i>	27
CHAPTER 4 OVERVIEW OF INFECTIOUS AGENTS	29
<i>TABLE 14 BIODEFENSE-RELATED PATHOGEN IDENTIFICATION WITH TEST AND TEST RESULT TIME (MINUTES)</i>	29
CATEGORY A BACTERIAL AGENTS	34
ANTHRAX	34
Signs and Symptoms	35
Detection Methods	35
<i>TABLE 15 RAPID TESTS TO DETECT ANTHRAX</i>	35
Vaccine Availability	36
Prevention/Treatment Protocols	36

<b>TOPIC</b>	<b>PAGE NO.</b>
PLAGUE (YERSINIA PESTIS)	37
Signs and Symptoms	37
Detection Methods	37
<i>TABLE 16 RAPID TESTS TO DETECT YERSINIA PESTIS BACTERIA</i>	37
Prevention/Treatment Protocols	38
TULAREMIA	38
Signs and Symptoms	38
Detection Methods	39
<i>TABLE 17 RAPID TESTS TO DETECT FRANCISELLA TULARENSIS BACTERIA</i>	39
Vaccine Availability	39
Prevention/Treatment Protocols	40
CATEGORY A VIRAL AGENTS	40
SMALLPOX	40
Signs and Symptoms	40
Detection Methods	40
<i>TABLE 18 RAPID TESTS TO DETECT SMALLPOX</i>	40
Vaccine Availability	41
Prevention/Treatment Protocols	41
INFLUENZA	42
Signs and Symptoms	42
Detection Methods	42
<i>TABLE 19 RAPID TESTS TO DETECT PANDEMIC INFLUENZA</i>	42
Vaccine Availability	43
Prevention/Treatment Protocols	43
VIRAL HEMORRHAGIC FEVERS	43
Ebola Virus	43
Signs and Symptoms	44
Detection Methods	44
<i>TABLE 20 RAPID TESTS TO DETECT EBOLA HEMORRHAGIC FEVER</i>	44
Vaccine Availability	44
<i>TABLE 21 VACCINES IN TESTING FOR EBOLA HEMORRHAGIC FEVER</i>	45
Treatment Protocols	45
<i>TABLE 22 PHARMACEUTICALS IN TESTING FOR EBOLA HEMORRHAGIC FEVER</i>	45
Marburg Virus	46
Signs and Symptoms	46
Detection Methods	46
<i>TABLE 23 RAPID TEST TO DETECT MARBURG HEMORRHAGIC FEVER</i>	46
Vaccine Availability	47
Treatment Protocols	47
CATEGORY B BACTERIAL AGENTS	47
BRUCELLOSIS	47
Signs and Symptoms	47
Detection Methods	48
<i>TABLE 24 RAPID TESTS TO DETECT BRUCELLA</i>	48
Vaccine Availability	48
Treatment Protocols	48
SALMONELLA	48

<b>TOPIC</b>	<b>PAGE NO.</b>
Signs and Symptoms	49
Detection Methods	49
<i>TABLE 25 RAPID TESTS TO DETECT SALMONELLA</i>	49
Vaccine Availability	49
Treatment Protocols	49
<b>E. COLI</b>	49
Signs and Symptoms	50
Detection Methods	50
<i>TABLE 26 RAPID TESTS TO DETECT E. COLI</i>	50
Vaccine Availability	50
Treatment Protocols	50
<b>GLANDERS</b>	50
Signs and Symptoms	50
Detection Methods	51
<i>TABLE 27 RAPID TESTS TO DETECT GLANDERS</i>	51
Vaccine Availability	51
Treatment Protocols	51
<b>MELIOIDOSIS</b>	51
Signs and Symptoms	52
Detection Methods	52
<i>TABLE 28 RAPID TEST TO DETECT MELIOIDOSIS</i>	52
Vaccine Availability	52
Treatment Protocols	52
<b>PSITTACOSIS</b>	53
Signs and Symptoms	53
Detection Methods	53
<i>TABLE 29 RAPID TESTS TO DETECT PSITTACOSIS</i>	53
Vaccine Availability	53
Treatment Protocols	53
<b>Q FEVER</b>	53
Signs and Symptoms	54
Detection Methods	54
<i>TABLE 30 RAPID TESTS TO DETECT Q FEVER</i>	54
Vaccine Availability	54
Treatment Protocols	55
<b>STAPHYLOCOCCAL ENTEROTOXIN B (SEB)</b>	55
Signs and Symptoms	55
Detection Methods	55
<i>TABLE 31 RAPID TESTS TO DETECT SEB</i>	55
Vaccine Availability	56
Treatment Protocols	56
<b>TYPHOID FEVER</b>	56
Signs and Symptoms	56
Detection Methods	56
<i>TABLE 32 METHOD TO DETECT TYPHOID FEVER</i>	56
Vaccine Availability	57
<i>TABLE 33 VACCINES USED TO PREVENT TYPHOID INFECTIONS</i>	57

<b>TOPIC</b>	<b>PAGE NO.</b>
Treatment Protocols	57
<b>CHOLERA</b>	57
Signs and Symptoms	57
Detection Methods	57
<i>TABLE 34 RAPID TESTS TO DETECT CHOLERA</i>	57
Vaccine Availability	58
Treatment Protocols	58
<b>CRYPTOSPORIDIUM</b>	58
Signs and Symptoms	58
Detection Methods	59
<i>TABLE 35 METHODS TO DETECT CRYPTOSPORIDIUM</i>	59
Vaccine Availability	59
Treatment	59
<b>VIRAL ENCEPHALITIS</b>	59
Signs and Symptoms	60
Detection Methods	60
<i>TABLE 36 RAPID TESTS TO DETECT VIRAL ENCEPHALITIS</i>	60
Vaccine Availability	60
Treatment Protocols	61
<b>CATEGORY B TOXINS</b>	61
<b>RICIN</b>	61
Signs and Symptoms	61
Inhalation	61
Ingestion	61
Skin/Eye Exposure	62
Detection Methods	62
<i>TABLE 37 RAPID TESTS TO DIAGNOSE RICIN POISONING</i>	62
Vaccine Availability	63
Treatment Protocols	63
<b>BOTULISM</b>	63
Signs and Symptoms	63
Detection Methods	63
<i>TABLE 38 RAPID TESTS TO DETECT BOTULISM POISONING</i>	63
Vaccine Availability	64
<i>TABLE 39 VACCINES TO TREAT BOTULISM</i>	64
Treatment Protocols	64
<b>VACCINE STOCKPILING</b>	65
<i>TABLE 40 U.S. GOVERNMENT CONTRACTED MARKET FOR SNS VACCINES, 2013-2018 (\$ MILLIONS)</i>	65
<b>BIODEFENSE-RELATED VACCINE MARKET</b>	65
<i>TABLE 41 BIODEFENSE-RELATED VACCINES BY INDICATION, NAME AND MANUFACTURER</i>	66
<i>THERMOSTABLE VACCINES</i>	66
<b>CLASSES OF DRUGS THAT EFFECTIVELY TREAT BIODEFENSE-RELATED PATHOGENS</b>	66
<b>AMINOGLYCOSIDES</b>	67
<b>QUINOLONES</b>	67
<b>TETRACYCLINES</b>	67

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 42 MEDICATIONS TO TREAT SELECTED BIODEFENSE-RELATED PATHOGENS BY DISEASE, MEDICATION AND TYPE</i>	67
<i>FIGURE 2 ANTIBIOTICS USED TO TREAT BIODEFENSE-RELATED BACTERIAL THREATS (%)</i>	68
BARRIERS TO USING BIOLOGICAL WEAPONS	68
<i>TABLE 43 BARRIERS TO USING BIOLOGICAL WEAPONS</i>	69
CHAPTER 5 BIODEFENSE-RELATED PATHOGEN DETECTION DEVICES	71
<i>TABLE 44 PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN DETECTION DEVICES, THROUGH 2021 (\$ MILLIONS)</i>	71
PATHOGEN ID DEVICES BY TESTING METHOD	71
<i>TABLE 45 PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED DETECTION DEVICES BY TESTING METHOD, THROUGH 2021 (\$ MILLIONS)</i>	71
<i>FIGURE 3 SHARES OF BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION DEVICES BY TESTING METHOD, 2016 AND 2021 (%)</i>	72
TYPE OF DEVICE	73
<i>TABLE 46 PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED DETECTION DEVICES BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	73
<i>FIGURE 4 SHARES OF BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION DEVICES BY TYPE, 2016 AND 2021 (%)</i>	74
DIAGNOSTIC TOOLS	75
MASS SPECTROMETRY	75
<i>TABLE 47 PROJECTED BIODEFENSE-RELATED MASS SPECTROMETRY DEVICE MARKET, THROUGH 2021 (\$ MILLIONS)</i>	75
PCR	75
<i>TABLE 48 PROJECTED BIODEFENSE-RELATED PCR DEVICE MARKET, THROUGH 2021 (\$ MILLIONS)</i>	76
IMMUNOLOGICAL ANALYSIS	76
<i>TABLE 49 PROJECTED U.S. BIODEFENSE-RELATED IMMUNOLOGICAL DEVICE MARKET, THROUGH 2021 (\$ MILLIONS)</i>	77
BIOLOGICAL SENSORS	77
CELLULAR ANALYSIS AND NOTIFICATION OF ANTIGEN RISKS AND YIELDS (CANARY)	77
PHOTONIC SENSORS	77
FIBER-OPTIC BIOSENSORS	78
LAB-ON-CHIP BIOSENSORS	78
THE BIODEFENSE BIOSENSOR MARKET	79
<i>TABLE 50 PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED BIOLOGICAL SENSORS, THROUGH 2021 (\$ MILLIONS)</i>	79
CHAPTER 6 CURRENT RESEARCH, EMERGING THERAPIES, PATENTS AND MARKET OPPORTUNITIES	81
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE	81
<i>TABLE 51 PATHOGEN PHARMACEUTICAL PRODUCT PIPELINE</i>	81
PHARMACEUTICAL RESEARCH	81
BACTERIAL INFECTIONS: PRODUCTS IN DEVELOPMENT	81
Rapid Test for Plague	81
BARDA's Antibacterial Program	82
<i>TABLE 52 PHARMACEUTICALS IN BACTERIA BIOTHREAT PIPELINE BY COMPOUND NAME, STAGE OF DEVELOPMENT, APPLICATION, AND DEVELOPER</i>	82

<b>TOPIC</b>	<b>PAGE NO.</b>
VIRAL INFECTIONS: PRODUCTS IN DEVELOPMENT	82
BioCryst Pharmaceuticals	82
Toyama Chemical	83
TOXIN RESEARCH	83
Gene Therapy Treatment for Botulism	83
VACCINE RESEARCH	84
LAWRENCE LIVERMORE NATIONAL LABORATORY (LLNL)	84
ORGANIC VACCINES	84
PROFECTUS BIOSCIENCES	85
SOLIGENIX	85
TULANE UNIVERSITY (NEW ORLEANS, LA.)	85
PATHOGEN VACCINE PIPELINE	85
<i>TABLE 53 PANDEMIC VACCINES UNDER DEVELOPMENT, 2015</i>	86
VIRAL PRODUCT RESEARCH	86
AUTOIMMUNE TECHNOLOGIES	86
BIODEFENSE-RELATED DEVICE RESEARCH	87
OMNI ARRAY BIOTECHNOLOGY	87
NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY (BEIJING, CHINA)	87
BIOSENSORS USED IN SMARTPHONES	87
ANTHRAX DETECTION	88
I-DIAGNOSTICS AND TIRF LABS	88
GEORGIA TECH RESEARCH INSTITUTE	88
CARBON NANOTUBE THIN FILM BIOSENSORS FOR WHOLE VIRUS DETECTION	89
MOLYBDENUM DISULFIDE BIOSENSORS	89
PATENTS	89
PATENTS BY NUMBER, COMPANY, TYPE OF DEVICE, DESCRIPTION, DATE OF ISSUE	90
<i>TABLE 54 RAPID PATHOGEN IDENTIFICATION PATENTS: NUMBER, COMPANY, TYPE OF DEVICE, DESCRIPTION AND DATE OF ISSUE, AUGUST 2011-JUNE 2015</i>	90
PATENTS BY MANUFACTURER	95
<i>TABLE 55 NUMBER OF PATENTS BY MANUFACTURER, AUGUST 2011-JUNE 2015</i>	95
<i>TABLE 56 PATENTS BY FUNCTION AND COMPANY AUGUST 2011-JUNE 2015</i>	95
PHARMACEUTICAL MARKET OPPORTUNITIES/CHALLENGES	96
VACCINE MARKET OPPORTUNITIES/CHALLENGES	96
DEVICE MARKET OPPORTUNITIES/CHALLENGES	96
CHALLENGES	96
OPPORTUNITIES	97
Rapid Assays	97
THE IMPACT OF GLOBAL POLITICAL/SOCIETAL CHANGES	97
SOCIETAL CHANGES	98
CHAPTER 7 U.S. AGENCIES AND THEIR PURPOSES	100
UNITED STATES DISEASE STRATEGY	100
<i>TABLE 57 SELECTED EMERGING INFECTIOUS DISEASE SINCE 1975 BY NAME, YEAR IDENTIFIED, ESTIMATED GLOBAL IMPACT AND MORTALITY PERCENTAGE</i>	101
DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)	101
PROJECT BIOSHIELD	101



<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 5 PERCENTAGE OF PROJECT BIOSHIELD FUNDS USED TO ACQUIRE COUNTERMEASURES, 2004-2014 (%)</i>	102
<b>PANDEMIC AND ALL-HAZARDS PREPAREDNESS REAUTHORIZATION</b>	102
Pandemic and All-Hazards Preparedness Reauthorization Act of 2013	102
Title I: Strengthening Preparedness and Response for Public Health Emergencies	103
Title II: Optimizing State and Local All-Hazards Preparedness and Response	103
Title III: Enhancing Medical Countermeasure Review	103
Title IV: Accelerating Medical Countermeasure Advanced Research and Development	104
<b>BARDA</b>	104
<b>CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)</b>	104
<b>NATIONAL INSTITUTES OF HEALTH (NIH)</b>	105
<b>U.S. FOOD AND DRUG ADMINISTRATION (FDA)</b>	105
<b>FOOD SAFETY AND MODERNIZATION ACT (FSMA)</b>	105
Key Initiatives of the Legislation	105
Prevention	106
Enhanced Partnerships	107
<b>CHAPTER 8 COMPANY DIRECTORY</b>	110
<b>DIAGNOSTIC PRODUCTS</b>	110
<b>20/20 GENESYSTEMS, INC.</b>	110
Business Overview	110
Product	110
<i>TABLE 58 20/20 DIAGNOSTIC PRODUCT</i>	110
<b>ADVNT BIOTECHNOLOGIES</b>	110
Business Overview	111
Products	111
<i>TABLE 59 ADVNT DETECTION PRODUCTS</i>	111
<b>AETHLON MEDICAL</b>	111
Business Overview	111
Products	112
<i>TABLE 60 AETHLON MEDICAL PRODUCTS</i>	112
<b>ALERE</b>	112
Business Overview	112
Products	112
<i>TABLE 61 ALERE DIAGNOSTIC PRODUCTS</i>	112
<b>ALEXETER TECHNOLOGIES</b>	113
Business Overview	113
Products	113
<i>TABLE 62 ALEXETER TECHNOLOGIES DIAGNOSTIC PRODUCTS</i>	113
<b>ALPHA DIAGNOSTIC INTERNATIONAL</b>	113
Business Overview	113
Products	114
<i>TABLE 63 ALPHA DIAGNOSTIC INTERNATIONAL DIAGNOSTIC PRODUCTS</i>	114
<b>ANP TECHNOLOGIES</b>	114
Business Overview	114

<b>TOPIC</b>	<b>PAGE NO.</b>
Products	115
<i>TABLE 64 ANP TECHNOLOGIES DIAGNOSTIC PRODUCTS</i>	115
ATLAS LINK BIOTECH CO., LTD	115
Business Overview	115
Products	116
<i>TABLE 65 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS</i>	116
BATTELLE	116
Business Overview	116
Products	117
<i>TABLE 66 BATTELLE DIAGNOSTIC PRODUCTS</i>	117
BB DETECTION	117
Business Overview	117
Product	117
<i>TABLE 67 BB DETECTION DIAGNOSTIC PRODUCT</i>	117
BERTIN TECHNOLOGIES	118
Business Overview	118
Products	118
<i>TABLE 68 BERTIN TECHNOLOGIES DIAGNOSTIC PRODUCTS</i>	118
BIODETECTION INSTRUMENTS	118
Business Overview	118
Product	119
<i>TABLE 69 BIODETECTION INSTRUMENTS DIAGNOSTIC PRODUCT</i>	119
BIOFIRE DEFENSE	119
Business Overview	119
Products	120
<i>TABLE 70 BIOFIRE DEFENSE PRODUCTS</i>	120
BIOMEME	120
Business Overview	120
Product	120
<i>TABLE 71 BIOMEME BIODEFENSE-RELATED DIAGNOSTIC PRODUCT</i>	120
BIOMERIEUX, INC.	121
Business Overview	121
Products	121
<i>TABLE 72 BIOMERIEUX BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS</i>	121
BIOSEARCH TECHNOLOGIES	121
Business Overview	121
Product	122
<i>TABLE 73 BIOSEARCH TECHNOLOGIES DIAGNOSTIC PRODUCT</i>	122
BIOTECH INTERNATIONAL	122
Business Overview	122
Product	122
<i>TABLE 74 BIOTECH INTERNATIONAL BIODEFENSE-RELATED DIAGNOSTIC PRODUCT</i>	122
BRUKER DETECTION	123
Business Overview	123
Product	123
<i>TABLE 75 BRUKER BIODEFENSE-RELATED DIAGNOSTIC PRODUCT</i>	123
CANGENE CORP. (SEE EMERGENT BIOSOLUTIONS)	123

<b>TOPIC</b>	<b>PAGE NO.</b>
CERES NANOSCIENCES, INC.	123
Business Overview	123
CHEMRING DETECTION SYSTEMS	124
Business Overview	124
Product	124
<i>TABLE 76 CHEMRING BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS</i>	124
CORGENIX MEDICAL CORP	124
Business Overview	125
Product	125
<i>TABLE 77 CORGENIX DIAGNOSTIC PRODUCT</i>	125
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.	125
Business Overview	125
<i>TABLE 78 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	125
DIATHERIX	126
Business Overview	126
Product	126
<i>TABLE 79 DIATHERIX DIAGNOSTIC PRODUCT</i>	126
ELECTRONIC SENSOR TECHNOLOGY, INC.	126
Business Overview	126
Product	127
<i>TABLE 80 ELECTRONIC SENSOR TECHNOLOGY DIAGNOSTIC PRODUCT</i>	127
ENVIRONICS OY	127
Business Overview	127
Products	127
<i>TABLE 81 ENVIRONICS DIAGNOSTICS PRODUCTS</i>	127
HAZTECH SYSTEMS	128
Business Overview	128
Products	128
<i>TABLE 82 HAZTECH BIODEFENSE-RELATED PRODUCTS</i>	128
INBIOS INTERNATIONAL, INC.	128
Business Overview	128
Products	129
<i>TABLE 83 INBIOS DIAGNOSTICS PRODUCTS</i>	129
INTEGRATED NANO-TECHNOLOGIES	129
Business Overview	129
Product	129
<i>TABLE 84 INTEGRATED NANO-TECHNOLOGIES DIAGNOSTICS PRODUCT</i>	129
MENON BIOSENSORS, INC.	130
Business Overview	130
Product	130
<i>TABLE 85 MENON BIOSENSORS DIAGNOSTIC PRODUCT</i>	130
MESO SCALE DEFENSE	130
Business Overview	130
Products	131
<i>TABLE 86 MESO SCALE DEFENSE DIAGNOSTICS PRODUCTS</i>	131
NANOLOGIX	131
Business Overview	131

<b>TOPIC</b>	<b>PAGE NO.</b>
Product	131
<i>TABLE 87 NANOLOGIX DIAGNOSTICS PRODUCT</i>	131
NEW HORIZON DIAGNOSTIC CORP.	132
Business Overview	132
Products	132
<i>TABLE 88 NEW HORIZON DIAGNOSTICS PRODUCTS</i>	132
OXFORD NANOPORE TECHNOLOGIES, LTD.	132
Business Overview	133
Products	133
<i>TABLE 89 OXFORD NANOPORE TECHNOLOGIES DIAGNOSTIC PRODUCTS</i>	133
PATHSENSORS, INC.	133
Business Overview	133
Products	134
<i>TABLE 90 PATHSENSORS DIAGNOSTICS PRODUCTS</i>	134
POSITIVE ID CORP.	134
Business Overview	134
Products	135
<i>TABLE 91 POSITIVE ID DIAGNOSTICS PRODUCTS</i>	135
PROENGIN, INC.	135
Business Overview	135
Product	135
<i>TABLE 92 PROENGIN DIAGNOSTICS PRODUCT</i>	135
QIAGEN N.V.	136
Business Overview	136
Products	136
<i>TABLE 93 QIAGEN BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS</i>	136
QUANTUMDX GROUP	136
Business Overview	137
Product	137
<i>TABLE 94 QUANTUMDX BIODEFENSE-RELATED DIAGNOSTIC PRODUCT</i>	137
RESEARCH INTERNATIONAL, INC.	137
Business Overview	137
Product	137
<i>TABLE 95 RESEARCH INTERNATIONAL BIODEFENSE-RELATED DIAGNOSTIC PRODUCT</i>	137
REAL-TIME ANALYZERS, INC.	138
Business Overview	138
Product	138
<i>TABLE 96 REAL-TIME ANALYZERS DIAGNOSTIC PRODUCT</i>	138
RESPONSE BIOMEDICAL CORP.	138
Business Overview	138
Products	139
<i>TABLE 97 RESPONSE BIOMEDICAL DIAGNOSTIC PRODUCTS</i>	139
SANDIA NATIONAL LABORATORIES	139
Business Overview	139
Product	139
<i>TABLE 98 SANDIA NATIONAL LABORATORIES DIAGNOSTIC PRODUCT</i>	139
SMITHS DETECTION	140

<b>TOPIC</b>	<b>PAGE NO.</b>
Business Overview	140
Products	140
<i>TABLE 99 SMITHS DETECTION BIODEFENSE-RELATED PRODUCTS</i>	140
THERMO FISHER	140
Business Overview	141
Product	141
<i>TABLE 100 THERMO FISHER BIODEFENSE-RELATED PRODUCT</i>	141
TETRACORE	141
Business Overview	141
Products	142
<i>TABLE 101 TETRACORE BIODEFENSE-RELATED PRODUCTS</i>	142
VACCINES	142
BAVARIAN NORDIC A/S	142
Business Overview	142
Product	143
<i>TABLE 102 BAVARIAN NORDIC BIODEFENSE VACCINE PRODUCT</i>	143
CRUCELL HOLLAND B.V.	143
Business Overview	143
EMERGENT BIOSOLUTIONS	143
Business Overview	143
Products	144
<i>TABLE 103 EMERGENT BIOSOLUTIONS VACCINE PRODUCTS</i>	144
INOVIO PHARMCEUTICALS	144
Business Overview	144
Products	144
<i>TABLE 104 INOVIO PHARMACEUTICALS VACCINE PRODUCTS</i>	144
NOVAVAX	145
Business Overview	145
Products	145
<i>TABLE 105 NOVAVAX VACCINE PRODUCTS</i>	145
PHARMATHENE, INC.	145
Business Overview	145
Products	146
<i>TABLE 106 PHARMATHENE VACCINE PRODUCTS</i>	146
SOLIGENIX	146
Business Overview	146
TAPIMMUNE	146
Business Overview	147
PHARMACEUTICALS	147
GLAXOSMITHKLINE	147
Business Overview	147
Products	147
<i>TABLE 107 GLAXOSMITHKLINE PHARMACEUTICAL PRODUCTS</i>	147
MERCK	148
Business Overview	148
Products	148
<i>TABLE 108 MERCK BIODEFENSE-RELATED PHARMACEUTICAL PRODUCTS</i>	148

<b>TOPIC</b>	<b>PAGE NO.</b>
SAREPTA THERAPEUTICS	148
Business Overview	149
SIGA TECHNOLOGIES	149
Business Overview	149
Product	149
<i>TABLE 109 SIGA BIODEFENSE-RELATED PRODUCT</i>	149
NATIONAL LABORATORIES	150
LAWRENCE LIVERMORE NATIONAL LABORATORIES	150
Business Overview	150
SABIN VACCINE INSTITUTE	150
Business Overview	150

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION PRODUCTS, THROUGH 2021 (\$ MILLIONS)	7
TABLE 1 U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS A	12
TABLE 2 CLASS A PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD	13
TABLE 3 U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS B	13
TABLE 4 CLASS B PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD	14
TABLE 5 U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS C	14
TABLE 6 CLASS C PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD	15
TABLE 7 LIMITATIONS OF SOME COMMON ANALYSIS METHODS	16
TABLE 8 CHARACTERISTICS OF BIOSENSORS	18
TABLE 9 DETECT-TO-WARN MONITORING SYSTEMS	21
TABLE 10 VACCINES FOR PATHOGENS, BY DISEASE OR CONDITION, BRAND NAME AND MANUFACTURER, 2014	22
TABLE 11 COMMON PHARMACEUTICALS TO TREAT BIODEFENSE-RELATED PATHOGENS BY NAME, MANUFACTURER, DISEASE OR CONDITION, 2015	23
TABLE 12 MAJOR GOVERNMENT FUNDERS OF R & D WITH AMOUNT FUNDED, 2012-2014 (\$ BILLIONS)	25
TABLE 13 SELECTED MERGERS AND ACQUISITIONS IN THE BIODEFENSE IDENTIFICATION INDUSTRY, JANUARY 2013-JUNE 2015	27
TABLE 14 BIODEFENSE-RELATED PATHOGEN IDENTIFICATION WITH TEST AND TEST RESULT TIME (MINUTES)	29
TABLE 15 RAPID TESTS TO DETECT ANTHRAX	35
TABLE 16 RAPID TESTS TO DETECT YERSINIA PESTIS BACTERIA	37
TABLE 17 RAPID TESTS TO DETECT FRANCISELLA TULARENSIS BACTERIA	39
TABLE 18 RAPID TESTS TO DETECT SMALLPOX	40
TABLE 19 RAPID TESTS TO DETECT PANDEMIC INFLUENZA	42
TABLE 20 RAPID TESTS TO DETECT EBOLA HEMORRHAGIC FEVER	44
TABLE 21 VACCINES IN TESTING FOR EBOLA HEMORRHAGIC FEVER	45
TABLE 22 PHARMACEUTICALS IN TESTING FOR EBOLA HEMORRHAGIC FEVER	45
TABLE 23 RAPID TEST TO DETECT MARBURG HEMORRHAGIC FEVER	46
TABLE 24 RAPID TESTS TO DETECT BRUCELLA	48
TABLE 25 RAPID TESTS TO DETECT SALMONELLA	49
TABLE 26 RAPID TESTS TO DETECT E. COLI	50
TABLE 27 RAPID TESTS TO DETECT GLANDERS	51
TABLE 28 RAPID TEST TO DETECT MELIOIDOSIS	52
TABLE 29 RAPID TESTS TO DETECT PSITTACOSIS	53
TABLE 30 RAPID TESTS TO DETECT Q FEVER	54
TABLE 31 RAPID TESTS TO DETECT SEB	55
TABLE 32 METHOD TO DETECT TYPHOID FEVER	56
TABLE 33 VACCINES USED TO PREVENT TYPHOID INFECTIONS	57
TABLE 34 RAPID TESTS TO DETECT CHOLERA	57
TABLE 35 METHODS TO DETECT CRYPTOSPORIDIUM	59
TABLE 36 RAPID TESTS TO DETECT VIRAL ENCEPHALITIS	60
TABLE 37 RAPID TESTS TO DIAGNOSE RICIN POISONING	62
TABLE 38 RAPID TESTS TO DETECT BOTULISM POISONING	63

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 39 VACCINES TO TREAT BOTULISM	64
TABLE 40 U.S. GOVERNMENT CONTRACTED MARKET FOR SNS VACCINES, 2013-2018 (\$ MILLIONS)	65
TABLE 41 BIODEFENSE-RELATED VACCINES BY INDICATION, NAME AND MANUFACTURER	66
TABLE 42 MEDICATIONS TO TREAT SELECTED BIODEFENSE-RELATED PATHOGENS BY DISEASE, MEDICATION AND TYPE	67
TABLE 43 BARRIERS TO USING BIOLOGICAL WEAPONS	69
TABLE 44 PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN DETECTION DEVICES, THROUGH 2021 (\$ MILLIONS)	71
TABLE 45 PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED DETECTION DEVICES BY TESTING METHOD, THROUGH 2021 (\$ MILLIONS)	71
TABLE 46 PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED DETECTION DEVICES BY TYPE, THROUGH 2021 (\$ MILLIONS)	73
TABLE 47 PROJECTED BIODEFENSE-RELATED MASS SPECTROMETRY DEVICE MARKET, THROUGH 2021 (\$ MILLIONS)	75
TABLE 48 PROJECTED BIODEFENSE-RELATED PCR DEVICE MARKET, THROUGH 2021 (\$ MILLIONS)	76
TABLE 49 PROJECTED U.S. BIODEFENSE-RELATED IMMUNOLOGICAL DEVICE MARKET, THROUGH 2021 (\$ MILLIONS)	77
TABLE 50 PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED BIOLOGICAL SENSORS, THROUGH 2021 (\$ MILLIONS)	79
TABLE 51 PATHOGEN PHARMACEUTICAL PRODUCT PIPELINE	81
TABLE 52 PHARMACEUTICALS IN BACTERIA BIOTHREAT PIPELINE BY COMPOUND NAME, STAGE OF DEVELOPMENT, APPLICATION, AND DEVELOPER	82
TABLE 53 PANDEMIC VACCINES UNDER DEVELOPMENT, 2015	86
TABLE 54 RAPID PATHOGEN IDENTIFICATION PATENTS: NUMBER, COMPANY, TYPE OF DEVICE, DESCRIPTION AND DATE OF ISSUE, AUGUST 2011-JUNE 2015	90
TABLE 55 NUMBER OF PATENTS BY MANUFACTURER, AUGUST 2011-JUNE 2015	95
TABLE 56 PATENTS BY FUNCTION AND COMPANY AUGUST 2011-JUNE 2015	95
TABLE 57 SELECTED EMERGING INFECTIOUS DISEASE SINCE 1975 BY NAME, YEAR IDENTIFIED, ESTIMATED GLOBAL IMPACT AND MORTALITY PERCENTAGE	101
TABLE 58 20/20 DIAGNOSTIC PRODUCT	110
TABLE 59 ADVNT DETECTION PRODUCTS	111
TABLE 60 AETHLON MEDICAL PRODUCTS	112
TABLE 61 ALERE DIAGNOSTIC PRODUCTS	112
TABLE 62 ALEXETER TECHNOLOGIES DIAGNOSTIC PRODUCTS	113
TABLE 63 ALPHA DIAGNOSTIC INTERNATIONAL DIAGNOSTIC PRODUCTS	114
TABLE 64 ANP TECHNOLOGIES DIAGNOSTIC PRODUCTS	115
TABLE 65 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS	116
TABLE 66 BATTELLE DIAGNOSTIC PRODUCTS	117
TABLE 67 BB DETECTION DIAGNOSTIC PRODUCT	117
TABLE 68 BERTIN TECHNOLOGIES DIAGNOSTIC PRODUCTS	118
TABLE 69 BIODETECTION INSTRUMENTS DIAGNOSTIC PRODUCT	119
TABLE 70 BIOFIRE DEFENSE PRODUCTS	120
TABLE 71 BIOMEME BIODEFENSE-RELATED DIAGNOSTIC PRODUCT	120
TABLE 72 BIOMERIEUX BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS	121
TABLE 73 BIOSEARCH TECHNOLOGIES DIAGNOSTIC PRODUCT	122
TABLE 74 BIOTECH INTERNATIONAL BIODEFENSE-RELATED DIAGNOSTIC PRODUCT	122
TABLE 75 BRUKER BIODEFENSE-RELATED DIAGNOSTIC PRODUCT	123



<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 76 CHEMRING BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS	124
TABLE 77 CORGENIX DIAGNOSTIC PRODUCT	125
TABLE 78 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS	125
TABLE 79 DIATHERIX DIAGNOSTIC PRODUCT	126
TABLE 80 ELECTRONIC SENSOR TECHNOLOGY DIAGNOSTIC PRODUCT	127
TABLE 81 ENVIRONICS DIAGNOSTICS PRODUCTS	127
TABLE 82 HAZTECH BIODEFENSE-RELATED PRODUCTS	128
TABLE 83 INBIOS DIAGNOSTICS PRODUCTS	129
TABLE 84 INTEGRATED NANO-TECHNOLOGIES DIAGNOSTICS PRODUCT	129
TABLE 85 MENON BIOSENSORS DIAGNOSTIC PRODUCT	130
TABLE 86 MESO SCALE DEFENSE DIAGNOSTICS PRODUCTS	131
TABLE 87 NANOLOGIX DIAGNOSTICS PRODUCT	131
TABLE 88 NEW HORIZON DIAGNOSTICS PRODUCTS	132
TABLE 89 OXFORD NANOPORE TECHNOLOGIES DIAGNOSTIC PRODUCTS	133
TABLE 90 PATHSENSORS DIAGNOSTICS PRODUCTS	134
TABLE 91 POSITIVE ID DIAGNOSTICS PRODUCTS	135
TABLE 92 PROENGIN DIAGNOSTICS PRODUCT	135
TABLE 93 QIAGEN BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS	136
TABLE 94 QUANTUMDX BIODEFENSE-RELATED DIAGNOSTIC PRODUCT	137
TABLE 95 RESEARCH INTERNATIONAL BIODEFENSE-RELATED DIAGNOSTIC PRODUCT	137
TABLE 96 REAL-TIME ANALYZERS DIAGNOSTIC PRODUCT	138
TABLE 97 RESPONSE BIOMEDICAL DIAGNOSTIC PRODUCTS	139
TABLE 98 SANDIA NATIONAL LABORATORIES DIAGNOSTIC PRODUCT	139
TABLE 99 SMITHS DETECTION BIODEFENSE-RELATED PRODUCTS	140
TABLE 100 THERMO FISHER BIODEFENSE-RELATED PRODUCT	141
TABLE 101 TETRACORE BIODEFENSE-RELATED PRODUCTS	142
TABLE 102 BAVARIAN NORDIC BIODEFENSE VACCINE PRODUCT	143
TABLE 103 EMERGENT BIOSOLUTIONS VACCINE PRODUCTS	144
TABLE 104 INOVIO PHARMACEUTICALS VACCINE PRODUCTS	144
TABLE 105 NOVAVAX VACCINE PRODUCTS	145
TABLE 106 PHARMATHENE VACCINE PRODUCTS	146
TABLE 107 GLAXOSMITHKLINE PHARMACEUTICAL PRODUCTS	147
TABLE 108 MERCK BIODEFENSE-RELATED PHARMACEUTICAL PRODUCTS	148
TABLE 109 SIGA BIODEFENSE-RELATED PRODUCT	149

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION MARKET, BY TYPE OF DETECTION, 2016 AND 2021 (%)	8
FIGURE 1 U.S. GENERAL R&D FUNDING SOURCES, 2014 (%)	26
FIGURE 2 ANTIBIOTICS USED TO TREAT BIODEFENSE-RELATED BACTERIAL THREATS (%)	68
FIGURE 3 SHARES OF BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION DEVICES BY TESTING METHOD, 2016 AND 2021 (%)	72
FIGURE 4 SHARES OF BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION DEVICES BY TYPE, 2016 AND 2021 (%)	74
FIGURE 5 PERCENTAGE OF PROJECT BIOSHIELD FUNDS USED TO ACQUIRE COUNTERMEASURES, 2004-2014 (%)	102